Eli Lilly and Company

Ares Trading S.a.

James A Hoffmann

Richard Dennis DiMarchi

William F Heath, Jr

David L Smiley

James E Shields

David B Flora

Brigitte E Schoner

Margret B Basinski

John A Galloway

Ronald Norbert Hermeling

Jirong Lu

Peter K Lambooy

Chakravarthy Narasimhan

Ronald E Chance

Chakravarthy N N Narasimhan

The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

Glucagon-like peptide-1 crystals

This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.

FSH and FSH variant formulations, products and methods

FSH formulation

The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

Glucagon-like insulinotropic peptides, compositions and methods

Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.

GLP-1 formulations

Glucagon-like insulinotropic peptides compositions and methods

The invention provides extended-action GLP-1 based peptides and compositions that are useful for treating diabetes and minimize the risk of hypoglycemia.

Glucagon-like peptide-1 analogs

The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Anti-obesity proteins

The present invention provides novel compounds, which comprise an obesity protein analog complexed with a divalent metal cation, pharmaceutical formulations thereof, and methods of using such compounds for treating obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.

Growing community of inventors

Greenwood, IN, United States of America

James A Hoffmann